Discovering Centrally Linked Peripheral Molecular Signatures of Alzheimer's Disease
发现阿尔茨海默病的中心连锁外周分子特征
基本信息
- 批准号:10555727
- 负责人:
- 金额:$ 97.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-15 至 2028-02-29
- 项目状态:未结题
- 来源:
- 关键词:African AmericanAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAlzheimer&aposs disease pathologyAlzheimer&aposs disease related dementiaAlzheimer’s disease biomarkerAmericanAutopsyBiologicalBiological MarkersBloodBlood VesselsBlood specimenBrainBrain regionCell NucleusCerebrospinal FluidClinicClinicalCognitionCognitiveCollaborationsCommunitiesComplexDataDiagnosisDiagnosticDiseaseDisease ProgressionEarly DiagnosisEpigenetic ProcessEthnic PopulationFloridaFunctional disorderFutureGene Expression ProfileGenesGeneticGenomeImageIndividualKnowledgeLatinoLinkLongitudinal cohortMeasuresMolecularMolecular ProfilingMultiomic DataNatural ImmunityOutcomeParticipantPathway AnalysisPathway interactionsPatternPeripheralPhenotypePopulationPopulation HeterogeneityProteinsProteomeRNAResourcesSamplingSymptomsSynapsesTestingTherapeuticTherapeutic InterventionTranscriptTranslationsadvanced analyticsartificial neural networkbiomarker discoveryblood-based biomarkerbrain cellcell typecohortcomparativecost effectivedisease phenotypedisorder subtypelipidomemetabolomemethylomemulti-ethnicmultiple omicsmyelinationneuroimagingneuropathologynovelpatient stratificationperipheral bloodpersonalized medicineprecision medicinepreservationprognosticrandom foresttranscriptometranscriptome sequencingtranscriptomic profilingtranslational approachtranslational studyvalidation studies
项目摘要
SUMMARY ABSTRACT
Discovering Alzheimer’s disease (AD) biomarkers for early diagnosis, tracking of disease progression and timely
therapeutic interventions is a significant need. Despite the utility of existing neuroimaging and cerebrospinal fluid
biomarkers, there is an urgent need to develop cost-effective and blood-based biomarkers to apply at the
population level. Large-scale multi-omics studies identified a multitude of molecular perturbations in AD. These
discoveries support the rationale for discovery of peripheral biomarkers that capture the full spectrum of central
changes that occur in this disease. Our proposal aims to leverage combined blood and brain multi-omics data in
well-characterized cohorts to identify peripheral molecular signatures which reflect the central molecular
perturbations that occur in AD brains. We hypothesize that blood molecular signatures can serve as centrally-
linked peripheral biomarkers (CLPBM) since many brain multi-omics changes can also be observed in blood
and vice versa. As they are linked with brain molecular perturbations, such CLPBM can provide mechanistic
information on potential drivers of disease and its progression. CLPBM can also be expected to aid in patient
stratification according to biological subtypes and disease stage, ultimately paving the way for personalized
medicine. There are, however, no sizable studies that simultaneously analyze brain and blood samples from the
same individuals to discover centrally-linked peripheral molecular signatures (CLPMS) that can serve as future
centrally-linked peripheral biomarkers (CLPBM). In Project 1, we leverage three studies with complementary
strengths, Mayo Clinic Study of Aging, Alzheimer’s Disease Neuroimaging Initiative and Mayo Clinic Florida post-
mortem African American and Latino American cohorts, to accomplish our specific aims to: 1. Discover brain
region-specific CLPMS through molecular profiling (transcriptome, genome, methylome, proteome,
metabolome/lipidome) in up to 5 brain regions and in matched blood samples. 2. Identify cell-type specific
CLPMS through single nucleus transcriptome profiling across 5 brain regions and in matched blood samples. 3.
Establish CLPMS in diverse populations by profiling of same -omics measures across the same brain regions
from LA and AA participants. 4. Discover CLPMS that reflect biological subtypes and temporal progression of
AD through use of advanced analytics approaches of the molecular data. We expect to identify brain region and
cell-type specific CLPMS, which reflect the heterogeneous neuropathology in AD; associate with or drive
antemortem clinical, neuroimaging and cognitive progression and outcomes of AD; define biological subtypes
and predict molecular stage of AD in multi-ethnic populations. Findings from Project 1, together with those from
Projects 2 and 3, collectively comprising >20,000 multi-omics and >48,000 AD phenotypes from >3,700 multi-
ethnic participants will be analyzed applying our well-defined Roadmap to Translation approach to prioritize
CLPMS for translation to precision medicine biomarkers for AD. Further, the data, outcomes and knowledge
from this Project will be shared broadly and serve as an unprecedented resource for the research community.
摘要
发现阿尔茨海默病(AD)的生物标志物,用于早期诊断,跟踪疾病进展,
治疗干预是一个重要的需求。尽管现有的神经影像学和脑脊液检查
生物标志物,迫切需要开发具有成本效益的血液生物标志物,以应用于
人口水平。大规模的多组学研究确定了AD中的多种分子扰动。这些
这些发现支持了发现外周生物标志物的基本原理,
这种疾病发生的变化。我们的提案旨在利用血液和大脑多组学数据,
充分表征的队列,以确定反映中心分子的外周分子特征,
发生在AD大脑中的扰动。我们假设血液分子特征可以作为中枢-
连锁外周生物标志物(CLPBM),因为许多脑多组学变化也可以在血液中观察到
且反之亦然。由于它们与脑分子扰动有关,因此这种CLPBM可以提供机制性的
关于疾病及其进展的潜在驱动因素的信息。CLPBM也有望帮助患者
根据生物亚型和疾病阶段进行分层,最终为个性化
药然而,还没有大规模的研究同时分析大脑和血液样本,
相同的个体发现中央连锁的外周分子特征(CLPMS),可以作为未来
中心连锁外周生物标志物(CLPBM)。在项目1中,我们利用三项研究,
优势,马约诊所衰老研究,阿尔茨海默病神经影像学倡议和马约诊所佛罗里达后,
尸检非洲裔美国人和拉丁美洲裔美国人队列,以实现我们的具体目标:1。发现大脑
区域特异性CLPMS通过分子分析(转录组,基因组,甲基化组,蛋白质组,
代谢组/脂质组)中的代谢产物。2.识别细胞类型特异性
CLPMS通过5个脑区和匹配血液样本中的单核转录组分析。3.
通过分析相同脑区的相同组学指标,在不同人群中建立CLPMS
来自LA和AA的参与者。4.发现反映生物学亚型和时间进展的CLPMS
AD通过使用分子数据的先进分析方法。我们希望能够识别大脑区域,
细胞类型特异性CLPMS,反映了AD中的异质性神经病理学;与AD相关或驱动
AD的生前临床、神经影像学和认知进展和结局;定义生物学亚型
并预测多种族人群中AD的分子阶段。项目1的结果,以及
项目2和3,共同包括来自> 3,700个多组学的> 20,000个多组学和> 48,000个AD表型。
将应用我们定义良好的翻译路线图方法对少数民族参与者进行分析,
CLPMS用于转化为AD的精确医学生物标志物。此外,数据、成果和知识
该项目的成果将被广泛分享,并成为研究界前所未有的资源。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NILUFER ERTEKIN-TANER其他文献
NILUFER ERTEKIN-TANER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NILUFER ERTEKIN-TANER', 18)}}的其他基金
A Systems Approach to Targeting Innate Immunity in AD
针对 AD 中先天免疫的系统方法
- 批准号:
10246077 - 财政年份:2020
- 资助金额:
$ 97.58万 - 项目类别:
Integrating the exposome and methylome to inform brain molecular changes in ADRD across established diverse cohorts.
整合暴露组和甲基化组,以了解已建立的不同队列中 ADRD 的大脑分子变化。
- 批准号:
10657846 - 财政年份:2020
- 资助金额:
$ 97.58万 - 项目类别:
A Systems Approach to Targeting Innate Immunity in AD
针对 AD 中先天免疫的系统方法
- 批准号:
10475289 - 财政年份:2020
- 资助金额:
$ 97.58万 - 项目类别:
A Systems Approach to Targeting Innate Immunity in AD
针对 AD 中先天免疫的系统方法
- 批准号:
10251376 - 财政年份:2020
- 资助金额:
$ 97.58万 - 项目类别:
A Systems Approach to Targeting Innate Immunity in AD
针对 AD 中先天免疫的系统方法
- 批准号:
10506095 - 财政年份:2020
- 资助金额:
$ 97.58万 - 项目类别:
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in AD
利用弹性分子网络进行 AD 治疗发现
- 批准号:
10404635 - 财政年份:2018
- 资助金额:
$ 97.58万 - 项目类别:
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in AD
利用弹性分子网络进行 AD 治疗发现
- 批准号:
10170201 - 财政年份:2018
- 资助金额:
$ 97.58万 - 项目类别:
相似海外基金
Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
- 批准号:
24K18114 - 财政年份:2024
- 资助金额:
$ 97.58万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
- 批准号:
10089306 - 财政年份:2024
- 资助金额:
$ 97.58万 - 项目类别:
Collaborative R&D
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
- 批准号:
498288 - 财政年份:2024
- 资助金额:
$ 97.58万 - 项目类别:
Operating Grants
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
- 批准号:
498310 - 财政年份:2024
- 资助金额:
$ 97.58万 - 项目类别:
Operating Grants
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
- 批准号:
23K20339 - 财政年份:2024
- 资助金额:
$ 97.58万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
- 批准号:
2740736 - 财政年份:2024
- 资助金额:
$ 97.58万 - 项目类别:
Studentship
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
- 批准号:
2305890 - 财政年份:2024
- 资助金额:
$ 97.58万 - 项目类别:
Fellowship Award
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
- 批准号:
2406592 - 财政年份:2024
- 资助金额:
$ 97.58万 - 项目类别:
Standard Grant
McGill-MOBILHUB: Mobilization Hub for Knowledge, Education, and Artificial Intelligence/Deep Learning on Brain Health and Cognitive Impairment in Aging.
McGill-MOBILHUB:脑健康和衰老认知障碍的知识、教育和人工智能/深度学习动员中心。
- 批准号:
498278 - 财政年份:2024
- 资助金额:
$ 97.58万 - 项目类别:
Operating Grants
Welfare Enhancing Fiscal and Monetary Policies for Aging Societies
促进老龄化社会福利的财政和货币政策
- 批准号:
24K04938 - 财政年份:2024
- 资助金额:
$ 97.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)